These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12585754)

  • 1. A proposed ethical framework for prescription drug benefit allocation policy.
    Teagarden JR; Daniels N; Sabin JE
    J Am Pharm Assoc (Wash); 2003; 43(1):69-74. PubMed ID: 12585754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proposed ethical framework for prescription drug benefit allocation policy.
    Teagarden JR; Daniels N; Sabin JE
    J Am Pharm Assoc (Wash); 2003 Jan; 43(1):69-74. PubMed ID: 23945807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceuticals: Medicare Modernization Act--2005. End of Year Issue Brief.
    Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-21. PubMed ID: 16710928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policy making and roles of health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S88-99. PubMed ID: 19253491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis: from science to application.
    Berger ML; Teutsch S
    Med Care; 2005 Jul; 43(7 Suppl):49-53. PubMed ID: 16056009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription drug benefit design: the building blocks and their impact on cost.
    Kopenski F
    Benefits Q; 2008; 24(4):7-11. PubMed ID: 19048742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who is entitled to what?
    Lamm RD
    Healthc Financ Manage; 2003 Sep; 57(9):74-7. PubMed ID: 14503147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An ethical template for pharmacy benefits.
    Daniels N; Teagarden JR; Sabin JE
    Health Aff (Millwood); 2003; 22(1):125-37. PubMed ID: 12528844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public healthcare resource allocation and the Rule of Rescue.
    Cookson R; McCabe C; Tsuchiya A
    J Med Ethics; 2008 Jul; 34(7):540-4. PubMed ID: 18591290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public preferences and organized interests in health policy: state pharmacy assistance programs as innovations.
    Gray V; Lowery D; Godwin EK
    J Health Polit Policy Law; 2007 Feb; 32(1):89-129. PubMed ID: 17312326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of a hierarchical Bayes method for utility estimation in a choice-based conjoint analysis of prescription benefit plans including medication therapy management services.
    Wellman GS; Vidican C
    Res Social Adm Pharm; 2008 Sep; 4(3):218-30. PubMed ID: 18794033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic evaluations more and more important in healthcare decision making. Costs must be balanced against benefits also in studies on health economics].
    Lundkvist J
    Lakartidningen; 2006 Nov 15-21; 103(46):3624-7. PubMed ID: 17153872
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuing policy issues in Medicare prescription drug coverage.
    Cubanski J
    Issue Brief (Commonw Fund); 2004 Nov; (710):1-5. PubMed ID: 15597515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7 factors complicate ethical resource allocation decisions: we should be more aware of the issues most likely to produce conflicts.
    Hofmann PB
    Healthc Exec; 2011; 26(3):62-3. PubMed ID: 21612165
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.